Study of AD981 Versus Placebo in Obesity Hypoventilation Syndrome

Phase 2 Completed 15 enrolled Istituto Auxologico Italiano Apnimed · collab STM Pharma PRO srl · collab University of Florence · collab VIS Ethic Research Srl · collab

RandomizedCrossoverQuadruple-blindTreatment

Summary

This is a randomized, double blind, placebo-controlled, cross-over, phase II, single center efficacy study of AD981 in patients with obesity hypoventilation syndrome documented by polysomnography (PSG) and transcutaneous, overnight measurement of CO2 (PtcCO2).

Timeline

Start: 2022-06-21
Primary completion: 2024-05-08
Completion: 2024-05-08

Publications

Perger E, Parati G, Faini A, Gell L, Faverio P, Luppi F, Bertoli S, Brunani A, Bigagli E, Lombardi C, Taranto-Montemurro L. Acetazolamide Plus Atomoxetine for Obesity Hypoventilation Syndrome Treatment. Chest. 2026 Feb;169(2):527-537. doi: 10.1016/j.chest.2025.09.019. Epub 2025 Sep 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Acetazolamide	Small molecule	500 mg	Oral
Subject	Atomoxetine	Other / unclassified	100 mg	Oral

Study of AD981 Versus Placebo in Obesity Hypoventilation Syndrome

Summary

Timeline

Publications

Drugs

Indications